Follow-up research from the Pediatric Study of Hepatitis C (PEDS-C) trial reveals that children treated with peginterferon alpha (pegIFN?) for hepatitis C (HCV) display significant changes in height, weight, body mass index (BMI), and body composition. Results appearing in the August issue of Hepatology, a journal of the American Association for the Study of Liver Diseases, indicate that most growth-related side effects are reversible with cessation of therapy. However, in many children the height-for-age score had not returned to baseline two years after stopping treatment. In the U.S...
Realtime Related Tweets
invalid username or userid in get_avatar
gary carter died cmas cmas tcu dr. oz heart attack grill las vegas the heart attack grill
No comments:
Post a Comment